logo
episode-header-image
Mar 2023
24m 43s

Using Real-World Studies to Compare DMTs...

The European Committee for Treatment and Research in Multiple Sclerosis
About this episode

Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, and Maria Pia Sormani, Professor of Biostatistics at the University of Genoa, discuss the use of real-world data to compare disease-modifying treatments (DMTs) in multiple sclerosis, including the advantages and limitations of randomised control trials and observational studies. Hosted by Alan Thompson, Editor-in-Chief of the MS Journal and Professor at University College London. 

Up next
Aug 12
How Technology Is Transforming Multiple Sclerosis Care
Technology is opening new possibilities for how multiple sclerosis is monitored, treated and managed. In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Ellen Mowry of Johns Hopkins University and Prof. Letizia Leocani of Vita-Salute San Raffaele Univer ... Show More
31m 6s
Jul 30
Should High-Risk Populations Be Screened for Multiple Sclerosis?
Could multiple sclerosis one day be detected before symptoms appear? And if so, should we be actively screening people who are at higher risk? In this episode of the ECTRIMS–MS Journal collaboration series, host Prof. Anneke van der Walt, Controversies Editor at the Multiple Scle ... Show More
32m 12s
Jul 16
How Geography, Healthcare Systems and Access Shape the Multiple Sclerosis Journey
Where someone lives can profoundly influence their multiple sclerosis journey. While advances in diagnosis and treatment have transformed MS care in many parts of the world, millions of people still face significant barriers to diagnosis, specialist care and life-changing therapi ... Show More
27m 7s
Recommended Episodes
May 2022
Patient-Reported Outcomes in Clinical Trials
<p>JAMA Associate Editor Ethan Basch, MD, and Melanie Calvert, PhD, from the University of Birmingham, UK, discuss barriers to and strategies for including rigorous patient-reported outcomes in clinical trials, and reflect on Dr Calvert's recent JAMA paper on related ethical impl ... Show More
14m 26s
Mar 2025
Guidelines on disease-modifying treatment in MS: a decade-long update
The latest guidelines on disease-modifying treatment in multiple sclerosis (MS) from the Association of British Neurologists is discussed in this intercontinental podcast with perspectives from the UK, the USA, and Australia.   Participants: <ul> <li>Professor Alasdair Coles is H ... Show More
36m 5s
Mar 2023
MS Talks 2.0. Chasing A Cure: Natural Remedies
Some people believe that natural remedies could help cure Multiple Sclerosis, as opposed to traditional medication. To give us a better insight into the science and to debunk myths, we’re joined by the director of the Neurology Institute, at Harley Street Medical Center in Abu Dh ... Show More
13m 26s
Jun 2024
Sequential, Multiple Assignment, Randomized Trial Designs With Dr Kidwell
Kelley Kidwell, PhD, professor of biostatistics, University of Michigan, discusses Sequential, Multiple Assignment, Randomized Trial Designs with JAMA Statistical Editor Roger J. Lewis, MD, PhD. Related Content: Sequential, Multiple Assignment, Randomized Trial Designs 
13m 27s
May 2023
May 2023 Neurology Recall: Topics in Multiple Sclerosis
<p><span data-sheets-value= "{"1":2,"2":"The May 2023 Neurology Recall showcases five dynamic interviews around Multiple Sclerosis. This episode features conversations with Dr. Bruce Bebo on cost burden of MS in the United States; followed by an interview with Dr. Christian Corda ... Show More
1h 17m
Mar 2023
Hematopoietic Stem Cell Transplant in Secondary Progressive MS
tail spinning
21m 54s
Dec 2023
Adjustment for Baseline Characteristics in Randomized Clinical Trials
JAMA Statistical Editor Roger J. Lewis, MD, PhD, discusses Adjustment for Baseline Characteristics in Randomized Clinical Trial with Lars W. Andersen, MD, MPH, PhD, DMSc. Related Content: Adjustment for Baseline Characteristics in Randomized Clinical Trials 
18m 15s
Jul 2024
Tapping the Brakes on New Parkinson Disease Biological Staging
Dr. Matthew Barrett talks with Dr. Michael S. Okun about the caution and deliberation needed in understanding Parkinson disease biomarkers. Read the related viewpoint piece in JAMA Neurology. Disclosures can be found at Neurology.org. 
17m 45s
Listen to millions of songs and podcasts on Anghami